We are live on ! Find out more
RXRX icon

Recursion Pharmaceuticals
RXRX

267 hedge funds and large institutions have $1.74B invested in Recursion Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 112 increasing their positions, 52 reducing their positions, and 45 closing their positions.

New
Increased
Maintained
Reduced
Closed

115% more repeat investments, than reductions

Existing positions increased: 112 | Existing positions reduced: 52

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

2% less first-time investments, than exits

New positions opened: 44 | Existing positions closed: 45

1% less funds holding

Funds holding: 270 → 267 (-3)

8% less capital invested

Capital invested by funds: $1.89B → $1.74B (-$145M)

15.24% less ownership

Funds ownership: 109.46% → 94.22% (-15%)

42% less call options, than puts

Call options by funds: $11.4M | Put options by funds: $19.8M

Holders
267
Holders Change
-3
Holders Change %
-1.11%
% of All Funds
3.83%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
44
Increased
112
Reduced
52
Closed
45
Calls
$11.4M
Puts
$19.8M
Net Calls
-$8.4M
Net Calls Change
+$1.55M

Top Buyers

Rank Fund Capital Flow
1
AIM
ARK Investment Management
Florida
+$33.2M
2
State Street
State Street
Massachusetts
+$29.5M
3
BlackRock
BlackRock
New York
+$24.6M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$19.5M
5
DM
Deerfield Management
New York
+$16.6M

Top Sellers

Rank Fund Capital Flow
1
LCM
Laurion Capital Management
New York
-$21.8M
2
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
-$9.68M
3
GCM
Ghisallo Capital Management
Massachusetts
-$8.25M
4
UBS Group
UBS Group
Switzerland
-$6.09M
5
PA
Perceptive Advisors
New York
-$5.77M
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$10.1M +$3.36M +469,154 +44%
JP Morgan Chase
27
JP Morgan Chase
New York
$7.75M +$484K +67,464 +6%
Bank of America
28
Bank of America
North Carolina
$7.68M -$4.85M -676,040 -37%
LIP
29
Liontrust Investment Partners
United Kingdom
$7.42M – – –
N
30
Nuveen
North Carolina
$7.41M +$2.68M +373,632 +50%
Susquehanna International Group
31
Susquehanna International Group
Pennsylvania
$7.05M -$2.13M -297,031 -22%
Voloridge Investment Management
32
Voloridge Investment Management
Florida
$6.42M +$6.98M +973,583 New
CFM
33
Comprehensive Financial Management
California
$6.21M – – –
Bank of New York Mellon
34
Bank of New York Mellon
New York
$6.1M -$966K -134,686 -13%
UBS Group
35
UBS Group
Switzerland
$5.27M -$6.09M -849,190 -51%
VAS
36
Vestmark Advisory Solutions
Massachusetts
$4.83M -$373K -51,964 -7%
Barclays
37
Barclays
United Kingdom
$4.6M +$2.18M +304,278 +77%
CM
38
Cercano Management
Washington
$4.51M – – –
Rafferty Asset Management
39
Rafferty Asset Management
New York
$4.45M +$1.66M +231,547 +52%
WP
40
Woodline Partners
California
$4.42M +$49.2K +6,869 +1%
Lazard Asset Management
41
Lazard Asset Management
New York
$4.23M +$847K +118,150 +23%
TC
42
TwinBeech Capital
New York
$3.53M +$1.17M +163,832 +44%
Two Sigma Advisers
43
Two Sigma Advisers
New York
$3.23M +$388K +54,100 +12%
Ensign Peak Advisors
44
Ensign Peak Advisors
Utah
$2.7M – – –
BG
45
Bellevue Group
Switzerland
$2.59M -$236K -32,929 -8%
LPL Financial
46
LPL Financial
California
$2.38M +$294K +40,969 +13%
Swiss National Bank
47
Swiss National Bank
Switzerland
$2.35M +$13.6K +1,900 +0.5%
RhumbLine Advisers
48
RhumbLine Advisers
Massachusetts
$2.05M +$209K +29,120 +10%
Simplex Trading
49
Simplex Trading
Illinois
$1.88M +$1.36M +189,941 +200%
Osaic Holdings
50
Osaic Holdings
Arizona
$1.85M +$441K +61,519 +28%
1
2
3 4 5

RXRX Hedge Fund Activity: Q3 2024 in Review

267 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q3 2024, worth a combined $1.74B — down 7.7% from $1.89B a quarter earlier.

Sellers outnumbered buyers: 45 funds closed out of RXRX and 44 opened new positions — a net loss of 1 holder — while 52 trimmed existing stakes and 112 added.

The largest buyer was ARK Investment Management, adding an estimated $33.2M. The largest seller was Laurion Capital Management, exiting entirely with an estimated $21.8M sold.

  • 267 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q3 2024, down from 270 in Q2 2024.
  • Funds reported $1.74B of Recursion Pharmaceuticals stock for Q3 2024, down 7.7% quarter-over-quarter.
  • 44 funds opened new Recursion Pharmaceuticals positions in Q3 2024 and 45 closed out, a net change of -1 holder.
  • The largest Recursion Pharmaceuticals buyer in Q3 2024 was ARK Investment Management, an estimated $33.2M added.
  • The largest Recursion Pharmaceuticals seller in Q3 2024 was Laurion Capital Management, an estimated $21.8M sold.

Based on aggregated 13F filings for Q3 2024.